092. RISK OF FRAGILITY FRACTURE OVER 10 YEARS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: A UK POPULATION STUDY

Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study

BACKGROUND Glucocorticoids are associated with increased fracture risk and are the mainstay of treatment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, fracture risk in these conditions has not been previously quantified. The aim of this study was to quantify the risk of fracture among patients with PMR and GCA. METHODS A retrospective cohort study was conducted usin...

The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population

BACKGROUND To update community-based prevalence values for Polymyalgia Rheumatic (PMR) and Giant Cell Arteritis (GCA) using case record review supplemented by population survey and subsequent clinical review. METHODS Clinical data were obtained from case records of a large primary care practice in Norfolk, UK and reviewed for diagnoses of GCA and PMR. In addition postal survey was carried out...

Polymyalgia rheumatica and giant cell arteritis.

The subjects of the study were 112 patients with rheumatic polymyalgia (RPM) and giant-cell arteritis (GSA). The study shows that RPM and GSA are complicated by cerebral flow disturbances and myocardial infarction. Therapy with prednisolone and non-steroid antiinflammatory drugs reduces the risk of these complications and lethal outcome in patients with RPM and GSA.

Amyloidosis and giant cell arteritis/polymyalgia rheumatica.

Giant cell arteritis and polymyalgia rheumatica.

The close relationship between giant cell arteritis and polymyalgia rheumatica has not been clearly explained. These disorders affect the same patient population and often coexist in the same person. Monitoring of the erythrocyte sedimentation rate is a useful tool in both diagnosis and treatment. Management with varying doses of prednisone has proved effective in resolving symptoms.